Compare CPHI & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPHI | AYTU |
|---|---|---|
| Founded | N/A | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.2M | 27.4M |
| IPO Year | 2008 | 2015 |
| Metric | CPHI | AYTU |
|---|---|---|
| Price | $0.70 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 18.9K | ★ 29.1K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,144,268.00 | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 277.47 |
| 52 Week Low | $0.38 | $1.65 |
| 52 Week High | $2.00 | $3.07 |
| Indicator | CPHI | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 45.74 | 49.38 |
| Support Level | $0.54 | $2.17 |
| Resistance Level | $0.89 | $2.32 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 0.00 | 55.56 |
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.